SOHO Announces SEHH/SETH Joint Session With Dr. Garcia-Manero
The Society of Hematologic Oncology (SOHO) will be holding a joint session with two Spain-based hematology societies: la Sociedad Española de Hematología y
Society Updates
Myelodysplastic Syndromes
News
Primary analysis finds luspatercept reduces transfusion dependence in lower-risk MDS
Luspatercept is more effective than epoetin alfa in achieving transfusion independencin anemia patients with lower-risk myelodysplastic syndromes (MDS), according to a primary analysis
Leukemia
Acute Lymphoblastic Leukemia
Salvage therapies show high remission rate in relapsed Ph+ ALL
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who relapsed after frontline ponatinib-based therapies had a high response rate to salvage treatments,
Educational Resources
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Meet-the-Professor session with Natalie Callander, MD
This Meet-the-Professor session in multiple myeloma is delivered by Natalie Callander, MD, of the University of Wisconsin. Dr. Callander as part of the
Educational Resources
Jerald Radich, MD, hosts session on transplantation in CML at SOHO 2024
For more educational resources, become a SOHO member for free at soho.click/join.
Meeting News
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Nitin Jain, MD, on Innovative Therapies in CLL
Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, and Nitin Jain,
Myeloproliferative Neoplasms
Primary Myelofibrosis
Fedratinib effective in patients with myelofibrosis previously treated with ruxolitinib
Results from the FREEDOM2 phase 3 trial supported the efficacy of fedratinib versus best available therapy (BAT) in patients with myelofibrosis previously treated
Lymphoma
Mantle Cell Lymphoma
Acalabrutinib granted Priority Review for patients with untreated MCL
The US Food and Drug Administration (FDA) has granted Priority Review status to the supplemental New Drug Application (sNDA) for acalabrutinib, a Bruton
Meeting News
Momelotinib has greater anemia-related benefits in myelofibrosis
Momelotinib was associated with greater anemia-related benefits in patients with myelofibrosis, according to an analysis presented at the 12th Annual Meeting of the
Meeting News
Meta-Analysis Investigates Daratumumab-Integrated Quadruple Therapy for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
A meta-analysis suggests that incorporating daratumumab into standard triplet therapy for newly diagnosed, transplant-eligible patients with multiple myeloma (MM) is associated with higher